NPHCOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
NUTRA PHARMA CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $806.69K
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Dec 31, 2025, from 13F filings
Held by institutions
0.0%
0M of 7.16B shares
Institutional holders
1
1 new, 0 sold out
Net institutional buying
0M
In Q4 2025
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Pure Raw Supplies, LLC | 12,000,000 | 100.00% | 13D (active) | Aug 21, 2026 |
Top institutional holders
13F holdings as of Dec 31, 2025
| Holder | Shares | % of NPHC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Motiv8 Investments LLC | 500 | 0.00% | $0 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q4 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2022 | 1 | 1M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q3 2022 | 2 | 1M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2022 | 2 | 1M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2022 | 3 | 1M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2021 | 3 | 1M | 0.0% | 0 / 0 | 0 / 1 | 0M | 1M |
| Q3 2021 | 4 | 1M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2021 | 4 | 1M | 0.0% | 2 / 0 | 0 / 1 | 1M | 0M |
| Q1 2021 | 3 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
| Q4 2020 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2020 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2020 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pure Raw Supplies, LLC | 10% owner | 12,000,000 | 0.17% | Sep 1, 2026 |
| Rik J. Deitsch | 10% owner | 0 | – | Sep 1, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rik J. Deitsch 10% owner | Aug 21, 2026 | Gift | −12,000,000 | – | – | 0 |
| Rik J. Deitsch President, CEO, Director | Nov 15, 2021 | Buy | +3,000,000 | – | – | 3,000,000 |
| Rik J. Deitsch President, CEO, Director | Nov 15, 2021 | Buy | +9,000,000 | – | – | 12,000,000 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Dec 19, 2016 | Buy | +15,000,000 | $0.01 | $150.00K | 43,298,859 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Jul 5, 2016 | Buy | +15,000,000 | $0.01 | $150.00K | 28,298,859 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Jun 28, 2016 | Award | +4,000,000 | $0.01 | $40.00K | 13,298,859 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Jun 13, 2015 | Award | +4,000,000 | $0.19 | $760.00K | 9,298,859 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Dec 11, 2014 | Award | +506,900 | $0.24 | $121.66K | 5,298,859 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Apr 10, 2014 | Buy | +1,250,000 | $0.08 | $100.00K | 4,791,959 |
| Garry Pottruck Director | Nov 25, 2013 | Award | +6,890,000 | $0.01 | $68.90K | 17,815,000 |
| Harold Henry Rumph President - ReceptoPharm, Director | Nov 25, 2013 | Award | +7,400,000 | $0.01 | $74.00K | 35,000,000 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Nov 25, 2013 | Award | +11,760,000 | $0.01 | $117.60K | 141,678,334 |
| Stewart Alan Lonky Director | Oct 18, 2013 | Returned to company | +70,000 | $0.01 | $700 | 20,220,000 |
| Harold Henry Rumph President - ReceptoPharm, Director | Sep 9, 2013 | Buy | +14,800,000 | – | – | 27,600,000 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Sep 9, 2013 | Buy | +25,000,000 | – | – | 129,918,334 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Jun 27, 2013 | Buy | +25,000,000 | – | – | 104,918,334 |
| Stewart Alan Lonky Director | Mar 8, 2013 | Award | +7,730,000 | – | – | 20,150,000 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Dec 19, 2012 | Buy | +10,000,000 | $0.01 | $100.00K | 79,918,334 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Dec 10, 2012 | Buy | +200,000 | $0.01 | $2.00K | 69,918,334 |
| Garry Pottruck Director | Oct 18, 2012 | Award | +5,500,000 | $0.02 | $110.00K | 10,925,000 |
| Harold Henry Rumph President - ReceptoPharm, Director | Oct 18, 2012 | Award | +5,000,000 | $0.02 | $100.00K | 12,800,000 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Oct 18, 2012 | Award | +7,500,000 | $0.02 | $150.00K | 69,718,334 |
| Stewart Alan Lonky Director | Oct 18, 2012 | Award | +5,000,000 | – | – | 12,420,000 |
| Bruno Sartori – | Aug 30, 2012 | Sale | −303,990 | $0.01 | $3.04K | 240,000 |
| Bruno Sartori – | Jun 1, 2012 | Buy | +8,100 | $0.01 | $81 | 486,100 |
| Bruno Sartori – | May 31, 2012 | Buy | +10,000 | $0.01 | $100 | 478,000 |
| Bruno Sartori – | May 30, 2012 | Buy | +8,000 | $0.02 | $160 | 468,000 |
| Bruno Sartori – | May 22, 2012 | Buy | +7,000 | $0.01 | $70 | 460,000 |
| Bruno Sartori – | Apr 26, 2012 | Buy | +105,000 | $0.01 | $1.05K | 453,000 |
| Bruno Sartori – | Apr 25, 2012 | Buy | +68,000 | $0.01 | $680 | 348,000 |
| Bruno Sartori – | Apr 24, 2012 | Buy | +10,000 | $0.01 | $100 | 280,000 |
| Bruno Sartori – | Apr 23, 2012 | Buy | +25,000 | $0.01 | $250 | 270,000 |
| Bruno Sartori – | Apr 23, 2012 | Buy | +5,000 | $0.01 | $50 | 245,000 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Apr 23, 2012 | Buy | +148,000 | $1741.88 | $257.80M | 62,218,334 |
| Garry Pottruck Director | Feb 10, 2012 | Award | +2,875,000 | $0.02 | $57.50K | 5,425,000 |
| Harold Henry Rumph President - ReceptoPharm, Director | Feb 10, 2012 | Award | +4,000,000 | $0.02 | $80.00K | 7,800,000 |
| Bruno Sartori – | Feb 10, 2012 | Award | +240,000 | – | – | 240,000 |
| Stewart Alan Lonky Director | Feb 10, 2012 | Award | +4,400,000 | – | – | 7,420,000 |
| Rik J. Deitsch President, CEO, Director, 10% owner | Feb 10, 2012 | Award | +6,800,000 | – | – | 62,070,334 |
| Stewart Alan Lonky Director | Jan 20, 2011 | Buy | +10,000 | $0.13 | $1.30K | 3,020,000 |
| Stewart Alan Lonky Director | Dec 21, 2010 | Buy | +10,000 | $0.08 | $800 | 3,010,000 |
| David Michael Isserman – | Apr 13, 2010 | Sale | −110,000 | $0.37 | $40.70K | 3,202,160 |
| Harold Henry Rumph President - ReceptoPharm, Director | Apr 9, 2010 | Sale | −400,000 | $0.39 | $156.00K | 3,800,000 |
| Harold Henry Rumph Director | Feb 17, 2010 | Buy | −50,000 | $0.46 | $23.00K | 4,200,000 |
| Harold Henry Rumph Director | Feb 12, 2010 | Buy | −50,000 | $0.40 | $20.00K | 4,250,000 |
| Harold Henry Rumph Director | Feb 3, 2010 | Buy | −50,000 | $0.37 | $18.50K | 4,300,000 |
| Harold Henry Rumph Director | Jan 21, 2010 | Buy | −50,000 | $0.33 | $16.50K | 4,350,000 |
| Paul F. Reid Director | Jun 18, 2009 | Award | −7,000,000 | $0.03 | $210.00K | 0 |
| Stewart Alan Lonky Director | Mar 18, 2008 | Award | +2,500,000 | – | – | 3,000,000 |
| Stanley Jack Cherelstein Director | Mar 18, 2008 | Award | +2,500,000 | – | – | 3,000,000 |
| Rik J. Deitsch President, CEO, CFO, Director, 10% owner | Mar 14, 2008 | Buy | +48,000,000 | $0.03 | $1.44M | 54,500,000 |
| Rik J. Deitsch President, CEO, CFO, Director, 10% owner | Mar 13, 2008 | Buy | +5,000,000 | $0.03 | $150.00K | 6,500,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.